Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 4/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.38 |
| ▸ | ALPI | P09923 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.37 |
| ▸ | PYGL | P06737 | 1/20 | 0.37 |
| ▸ | PYGM | P11217 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835761 | 0.87 | ALB (0.39) | ALBMAOBHIF1APYGLPYGM | |
| SCHEMBL6818920 | 0.86 | ALB (0.42) | ALPLALBMAOBP2RY2GPR17 | |
| SCHEMBL6832994 | 0.85 | HIF1A (0.46) | ALBHIF1A | |
| SCHEMBL6830330 | 0.84 | SLC16A3 (0.44) | MAOB | |
| SCHEMBL6710401 | 0.84 | ALPL (0.39) | ALPLMAOBP2RY2GPR17ALPI | |
| SCHEMBL6713524 | 0.84 | ALPL (0.41) | ALPLMAOBP2RY2GPR17ALPI | |
| SCHEMBL6834401 | 0.83 | GPR27 (0.46) | ALBHIF1A | |
| SCHEMBL6833638 | 0.83 | KDM4E (0.41) | ALBHIF1APYGLPYGM | |
| SCHEMBL6830490 | 0.82 | HIF1A (0.55) | ALBHIF1A | |
| SCHEMBL6818222 | 0.82 | ALB (0.48) | ALBMAOBHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ALPL 2286/4885ALB 1417/4885MAOB 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.